Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialCraig H. Moskowitz, Jan Walewski, Auayporn Nademanee et al.|The Lancet|2015Cited by 740
Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN StudyAjay K. Gopal, Gilles Salles, Georg Heß et al.|Blood|2016Cited by 9